Savolitinib Plus Tagrisso Added About Five Months of Median Survival Over Chemo in MET-Driven Lung Cancer
Full SAFFRON results found that savolitinib plus Tagrisso improved overall and progression-free survival versus chemotherapy in EGFR-mutated lung cancer with MET changes, while highlighting important safety differences.
Medical Daily ·